|
 |
|||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference SAN DIEGO – April 19, 2004 – ADVENTRX Pharmaceuticals, Inc. (OTCBB: AVRX) announced today that the Company will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference, to be held April 27-28 at New York's Millennium Broadway Hotel. The presentation is scheduled for Tuesday, April 27 at 9:00 am EST. Nicholas Jon Virca, President and CEO of ADVENTRX, will present the latest developments for the Company's clinical programs, which include CoFactorT for the treatment of colorectal and pancreatic cancers, and BlockAide/CRT, ThiovirT and EradicAideT for the treatment of HIV/AIDS. In addition, Mr. Virca will provide an update on the Company's recent financing and operational plans. About ADVENTRX ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information on ADVENTRX can be found on the Company's website at www.adventrx.com. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: Company Contact: Evan Levine, ADVENTRX Pharmaceuticals, Inc. 858-271-9671 Investor Contact: Stephanie Carrington, The Ruth Group 646-536-7017 Media Contact: Cynthia Isaac, Ph.D., The Ruth Group 646-536-7028 For more information on Burnham Hill Partners, call 212-980-2200 |
